Rafael Holdings, Inc. (RFL) is a Real Estate · Real Estate Services company listed on NYSE. Price $1.99 (-3.40%), Market cap $0.07B, 52-week low–high $1.16 ~ $2.85.
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is Trappsol Cyclo, which is in phase 3 clinical trial being evaluated for the potential treatment of Niemann-Pick Disease Type C1 (NPC1), a rare, fatal and progressive genetic disorder; and CPI-613 (devimistat), a stable analog of normally transient, acylated catalytic inter
Financial statements, price targets, institutional (13F) holdings and related news for Rafael Holdings, Inc. are updated in real time on BlackAll Trade.
Rafael Holdings, Inc. trades at $1.99 (-3.40%). Real-time quotes and charts are available on BlackAll Trade.
Rafael Holdings, Inc. has a market cap of about $0.07B.
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, H